Is IPSC or PVLA more profitable?

Century Therapeutics' return on equity of -49.89% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Century Therapeutics N/A -49.89% -37.42% Palvella Therapeutics N/A -56.87% -42.50%

Does the media prefer IPSC or PVLA?

In the previous week, Palvella Therapeutics had 5 more articles in the media than Century Therapeutics. MarketBeat recorded 7 mentions for Palvella Therapeutics and 2 mentions for Century Therapeutics. Palvella Therapeutics' average media sentiment score of 0.96 beat Century Therapeutics' score of 0.62 indicating that Palvella Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Palvella Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RXRX or IPSC?

In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than Century Therapeutics. MarketBeat recorded 4 mentions for Recursion Pharmaceuticals and 2 mentions for Century Therapeutics. Recursion Pharmaceuticals' average media sentiment score of 0.89 beat Century Therapeutics' score of 0.62 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SEPN or IPSC?

In the previous week, Septerna had 6 more articles in the media than Century Therapeutics. MarketBeat recorded 8 mentions for Septerna and 2 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 0.62 beat Septerna's score of 0.20 indicating that Century Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is GHRS or IPSC more profitable?

GH Research's return on equity of -19.36% beat Century Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -19.36% -18.73% Century Therapeutics N/A -49.89% -37.42%

Does the media favor GHRS or IPSC?

In the previous week, GH Research had 2 more articles in the media than Century Therapeutics. MarketBeat recorded 4 mentions for GH Research and 2 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 0.62 beat GH Research's score of 0.47 indicating that Century Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is IPSC or BCAX more profitable?

Bicara Therapeutics' return on equity of -35.89% beat Century Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Century Therapeutics N/A -49.89% -37.42% Bicara Therapeutics N/A -35.89% -33.78%

Does the media prefer IPSC or BCAX?

In the previous week, Century Therapeutics and Century Therapeutics both had 2 articles in the media. Bicara Therapeutics' average media sentiment score of 0.94 beat Century Therapeutics' score of 0.62 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Bicara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Century Therapeutics (IPSC) Competitors

$2.45 +0.04 (+1.66%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$2.40 -0.06 (-2.24%)

As of 04:52 AM Eastern

Compare

IPSC vs. PVLA, RXRX, SEPN, GHRS, and BCAX

Should you buy Century Therapeutics stock or one of its competitors? MarketBeat compares Century Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Century Therapeutics include Palvella Therapeutics (PVLA), Recursion Pharmaceuticals (RXRX), Septerna (SEPN), GH Research (GHRS), and Bicara Therapeutics (BCAX). These companies are all part of the "pharmaceutical products" industry.

How does Century Therapeutics compare to Palvella Therapeutics?

Century Therapeutics (NASDAQ:IPSC) and Palvella Therapeutics (NASDAQ:PVLA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

In the previous week, Palvella Therapeutics had 5 more articles in the media than Century Therapeutics. MarketBeat recorded 7 mentions for Palvella Therapeutics and 2 mentions for Century Therapeutics. Palvella Therapeutics' average media sentiment score of 0.96 beat Century Therapeutics' score of 0.62 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Palvella Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Century Therapeutics' return on equity of -49.89% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.89%	-37.42%
Palvella Therapeutics	N/A	-56.87%	-42.50%

Century Therapeutics has higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	4.05	-$9.58M	-$1.14	N/A
Palvella Therapeutics	$42.81M	51.19	-$41.72M	-$4.17	N/A

Century Therapeutics presently has a consensus price target of $4.75, suggesting a potential upside of 93.88%. Palvella Therapeutics has a consensus price target of $199.53, suggesting a potential upside of 30.57%. Given Century Therapeutics' higher probable upside, equities research analysts clearly believe Century Therapeutics is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 2.4% of Century Therapeutics shares are held by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Century Therapeutics has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.15, suggesting that its share price is 115% less volatile than the broader market.

Summary

Century Therapeutics beats Palvella Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Century Therapeutics compare to Recursion Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than Century Therapeutics. MarketBeat recorded 4 mentions for Recursion Pharmaceuticals and 2 mentions for Century Therapeutics. Recursion Pharmaceuticals' average media sentiment score of 0.89 beat Century Therapeutics' score of 0.62 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Century Therapeutics has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -842.95%. Century Therapeutics' return on equity of -49.89% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%
Century Therapeutics	N/A	-49.89%	-37.42%

Recursion Pharmaceuticals presently has a consensus target price of $8.10, suggesting a potential upside of 120.71%. Century Therapeutics has a consensus target price of $4.75, suggesting a potential upside of 93.88%. Given Recursion Pharmaceuticals' higher probable upside, equities analysts clearly believe Recursion Pharmaceuticals is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Century Therapeutics has higher revenue and earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	26.04	-$644.76M	-$1.20	N/A
Century Therapeutics	$109.16M	4.05	-$9.58M	-$1.14	N/A

Recursion Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market.

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 2.4% of Century Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Century Therapeutics beats Recursion Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Century Therapeutics compare to Septerna?

Septerna (NASDAQ:SEPN) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Century Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Century Therapeutics	N/A	-49.89%	-37.42%

Septerna has a beta of 2.39, indicating that its stock price is 139% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market.

Septerna currently has a consensus price target of $45.78, suggesting a potential upside of 36.69%. Century Therapeutics has a consensus price target of $4.75, suggesting a potential upside of 93.88%. Given Century Therapeutics' higher possible upside, analysts clearly believe Century Therapeutics is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

50.2% of Century Therapeutics shares are held by institutional investors. 5.8% of Septerna shares are held by company insiders. Comparatively, 2.4% of Century Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Century Therapeutics has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	32.86	-$48.88M	-$0.81	N/A
Century Therapeutics	$109.16M	4.05	-$9.58M	-$1.14	N/A

In the previous week, Septerna had 6 more articles in the media than Century Therapeutics. MarketBeat recorded 8 mentions for Septerna and 2 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 0.62 beat Septerna's score of 0.20 indicating that Century Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Septerna beats Century Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Century Therapeutics compare to GH Research?

GH Research (NASDAQ:GHRS) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

56.9% of GH Research shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 2.4% of Century Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, GH Research had 2 more articles in the media than Century Therapeutics. MarketBeat recorded 4 mentions for GH Research and 2 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 0.62 beat GH Research's score of 0.47 indicating that Century Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

GH Research has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market.

GH Research's return on equity of -19.36% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
Century Therapeutics	N/A	-49.89%	-37.42%

GH Research presently has a consensus target price of $40.38, indicating a potential upside of 49.68%. Century Therapeutics has a consensus target price of $4.75, indicating a potential upside of 93.88%. Given Century Therapeutics' higher possible upside, analysts clearly believe Century Therapeutics is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Century Therapeutics has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A
Century Therapeutics	$109.16M	4.05	-$9.58M	-$1.14	N/A

Summary

GH Research and Century Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Century Therapeutics compare to Bicara Therapeutics?

Century Therapeutics (NASDAQ:IPSC) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

In the previous week, Century Therapeutics and Century Therapeutics both had 2 articles in the media. Bicara Therapeutics' average media sentiment score of 0.94 beat Century Therapeutics' score of 0.62 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bicara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bicara Therapeutics' return on equity of -35.89% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.89%	-37.42%
Bicara Therapeutics	N/A	-35.89%	-33.78%

Century Therapeutics presently has a consensus target price of $4.75, suggesting a potential upside of 93.88%. Bicara Therapeutics has a consensus target price of $30.27, suggesting a potential upside of 1.96%. Given Century Therapeutics' higher possible upside, research analysts plainly believe Century Therapeutics is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

Century Therapeutics has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.53, indicating that its stock price is 153% less volatile than the broader market.

50.2% of Century Therapeutics shares are owned by institutional investors. 2.4% of Century Therapeutics shares are owned by insiders. Comparatively, 13.8% of Bicara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Century Therapeutics has higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	4.05	-$9.58M	-$1.14	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A

Summary

Century Therapeutics and Bicara Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Century Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IPSC vs. The Competition

Export

Metric	Century Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$434.65M	$3.08B	$7.07B	$12.45B
Dividend Yield	N/A	1.86%	2.66%	6.16%
P/E Ratio	-2.15	19.38	27.27	24.87
Price / Sales	4.05	350.27	544.68	102.84
Price / Cash	181.20	57.53	48.53	58.59
Price / Book	1.35	4.28	10.95	6.54
Net Income	-$9.58M	$64.45M	$3.57B	$336.70M
7 Day Performance	6.99%	3.22%	2.29%	2.81%
1 Month Performance	3.81%	2.23%	1.36%	0.58%
1 Year Performance	351.20%	34.37%	36.68%	31.29%

Century Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IPSC Century Therapeutics	1.8601 of 5 stars	$2.45 +1.7%	$4.75 +93.9%	+338.5%	$434.65M	$109.16M	N/A	170	High Trading Volume
PVLA Palvella Therapeutics	3.0718 of 5 stars	$119.13 +0.2%	$199.53 +67.5%	+578.0%	$1.71B	$42.81M	N/A	N/A
RXRX Recursion Pharmaceuticals	2.9424 of 5 stars	$3.20 +0.5%	$8.10 +153.5%	-27.5%	$1.69B	$74.68M	N/A	400
SEPN Septerna	2.4617 of 5 stars	$37.13 +6.5%	$45.78 +23.3%	+216.8%	$1.67B	$45.95M	N/A	N/A	News Coverage
GHRS GH Research	3.4357 of 5 stars	$24.03 +8.8%	$40.38 +68.1%	+121.3%	$1.65B	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IPSC) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Century Therapeutics (IPSC) Competitors

IPSC vs. PVLA, RXRX, SEPN, GHRS, and BCAX

How does Century Therapeutics compare to Palvella Therapeutics?

Summary

How does Century Therapeutics compare to Recursion Pharmaceuticals?

Summary

How does Century Therapeutics compare to Septerna?

Summary

How does Century Therapeutics compare to GH Research?

Summary

How does Century Therapeutics compare to Bicara Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC vs. The Competition

Century Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Century Therapeutics (IPSC) Competitors

IPSC vs. PVLA, RXRX, SEPN, GHRS, and BCAX

How does Century Therapeutics compare to Palvella Therapeutics?

Does the media prefer IPSC or PVLA?

Is IPSC or PVLA more profitable?

Which has better valuation & earnings, IPSC or PVLA?

Do analysts rate IPSC or PVLA?

Do institutionals & insiders hold more shares of IPSC or PVLA?

Which has more volatility and risk, IPSC or PVLA?

Summary

How does Century Therapeutics compare to Recursion Pharmaceuticals?

Does the media refer more to RXRX or IPSC?

Is RXRX or IPSC more profitable?

Do analysts rate RXRX or IPSC?

Which has stronger valuation & earnings, RXRX or IPSC?

Which has more risk & volatility, RXRX or IPSC?

Do institutionals and insiders hold more shares of RXRX or IPSC?

Summary

How does Century Therapeutics compare to Septerna?

Is SEPN or IPSC more profitable?

Which has more risk & volatility, SEPN or IPSC?

Do analysts prefer SEPN or IPSC?

Do insiders and institutionals have more ownership in SEPN or IPSC?

Which has better earnings & valuation, SEPN or IPSC?

Does the media favor SEPN or IPSC?

Summary

How does Century Therapeutics compare to GH Research?

Do institutionals & insiders believe in GHRS or IPSC?

Does the media favor GHRS or IPSC?

Which has more risk and volatility, GHRS or IPSC?

Is GHRS or IPSC more profitable?

Do analysts recommend GHRS or IPSC?

Which has preferable earnings and valuation, GHRS or IPSC?

Summary

How does Century Therapeutics compare to Bicara Therapeutics?

Does the media prefer IPSC or BCAX?

Is IPSC or BCAX more profitable?

Do analysts prefer IPSC or BCAX?

Which has more risk and volatility, IPSC or BCAX?

Do insiders & institutionals hold more shares of IPSC or BCAX?

Which has stronger valuation & earnings, IPSC or BCAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC vs. The Competition

Century Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools